Experienced Executives Art Collins Is Appointed Senior Advisor of ExplORer Surgical and Denis Harrington to BOD

Former CEOs of Medtronic and BridgePoint Medical to advise ExplORer Surgical’s executive team and help advance its growth in the Med Device industry

October 13, 2020

Art Collins, former chairman and CEO of Medtronic, has been appointed senior advisor of ExplORer Surgical and Denis Harrington, former CEO of BridgePoint Medical, has been appointed to its Board of Directors. Collins’ and Harrington’s decades of commercial and entrepreneurial experience in the medical device field provide ExplORer Surgical and its executive team a valuable resource to help direct the company’s strategy.

Art Collins has over 30 years of experience in the medtech industry, first with Abbott Laboratories and later with Medtronic where he served as chairman & CEO from 2001 to 2008. During his 15-year tenure as CEO and COO of Medtronic, revenues and earnings per share grew at a compounded growth rate of over 15 percent. He is currently a member of Boeing’s board of directors and is a past director of Alcoa, Arconic, Cargill, Tennant, and US Bancorp. He also served as a member of the Board of Overseers of the Wharton School at the University of Pennsylvania and as chairman of AdvaMed, the medical technology industry association.

“We all know that 2020 has created a new normal for hospitals and medtech companies as they increasingly embrace remote and digital technology. ExplORer was well-positioned before the pandemic, and this year has accelerated the demand for their cutting-edge platform that helps ensure best practices and streamlines workflows to better ensure procedural proficiency,” said Collins. “I believe the company is well-positioned to achieve rapid growth and I am looking forward to my association with them.”

Harrington is the owner of Denis L Harrington Consulting, LLC, a management and strategy consulting firm he established after nearly 30 years of successful leadership in the medical device industry. He previously served as CEO for BridgePoint Medical and NexGen Medical, successfully leading BridgePoint from its development stage through commercialization and successful acquisition by Boston Scientific. Currently, he serves as an executive consultant and board director for several medical device companies.

“I am excited to join ExplORer Surgical’s Board of Directors,” said Harrington.  “I have spent over 30 years in the medical device business, and I am extremely impressed by ExplORer’s potential. As the healthcare ecosystem rapidly evolves and changes, platforms like ExplORer will play an increasingly critical role in delivering insight, information, and best practices to optimize outcomes and improve efficiencies in all healthcare procedure suites. ExplORer’s ability to deliver remote coaching and constantly update itself for continuous automated improvement make it an indispensable tool for med-tech sales reps to support complex procedures and deliver optimized service.”

ExplORer provides meaningful value to an organization’s functions and the surgical teams they work with, including sales, training, medical affairs, marketing, and research and development.

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.